• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    2/10/23 8:58:59 AM ET
    $NEO
    Precision Instruments
    Health Care
    Get the next $NEO alert in real time by email
    SC 13G/A 1 d279045dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    NeoGenomics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    64049M209

    (CUSIP Number)

    12/31/2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 64049M209    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Limited Partnership

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      Not Applicable

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      -

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      -

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      -

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.0%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      IA


    CUSIP No. 64049M209    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Investments GP LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      Not Applicable

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      -

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      -

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      -

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.0%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC


    CUSIP No. 64049M209    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Holdings LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      Not Applicable

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      -

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      -

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      -

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.0%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC


    CUSIP No. 64049M209    13G   

     

      1    

      NAME OF REPORTING PERSON

     

      Artisan Partners Asset Management Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

      Not Applicable

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      None

       6  

      SHARED VOTING POWER

     

      -

       7  

      SOLE DISPOSITIVE POWER

     

      None

       8  

      SHARED DISPOSITIVE POWER

     

      -

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      -

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

      ☐

     

      Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0.0%

    12  

      TYPE OF REPORTING PERSON (see Instructions)

     

      HC


    Item 1(a)

    Name of Issuer:

    NeoGenomics, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    9490 NeoGenomics Way, Fort Myers, Florida 33912

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    64049M209

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 12/31/2022):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    -

     

      (b)

    Percent of class:

    0.0% (based on 126,303,261 shares outstanding as of 11/4/2022)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

      (ii)

    shared power to vote or to direct the vote: -

      (iii)

    sole power to dispose or to direct the disposition of: None

      (iv)

    shared power to dispose or to direct the disposition of: -

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 2/10/2023

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,

    for itself and as the general partner of

    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,

    for itself and as the general partner of

    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 2/10/2023 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.


    EXHIBIT 1

    JOINT FILING AGREEMENT

    The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached.

    Dated: 2/10/2023

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,

    for itself and as the general partner of

    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,

    for itself and as the general partner of

    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC
    Get the next $NEO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEO

    DatePrice TargetRatingAnalyst
    7/30/2025Buy → Neutral
    BTIG Research
    7/29/2025Outperform → Mkt Perform
    William Blair
    5/15/2025Neutral
    Guggenheim
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    More analyst ratings

    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    Guggenheim initiated coverage on NeoGenomics

    Guggenheim initiated coverage of NeoGenomics with a rating of Neutral

    5/15/25 8:12:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    EVP, GC & Business Development Olivo Alicia C covered exercise/tax liability with 14 shares, decreasing direct ownership by 0.03% to 49,606 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/5/25 4:38:59 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

    New ctDNA-based test offers a flexible, guideline-driven solution for patients with advanced solid tumors when tissue is limited or unavailable NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. "The launch of our liquid biopsy test positions us at the forefront of the prec

    7/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

    7/1/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    8/8/25 4:03:26 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 10-Q filed by NeoGenomics Inc.

    10-Q - NEOGENOMICS INC (0001077183) (Filer)

    7/29/25 7:22:17 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    7/29/25 7:08:17 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

    6/24/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    3/18/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    PacBio Announces Appointment of Chris Smith to Board of Directors

    MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

    1/30/25 9:05:00 AM ET
    $NEO
    $PACB
    Precision Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

    7/1/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports First Quarter 2025 Results

    Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

    4/29/25 7:30:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care